Safe on first.

CRISPR-edited autologous T-cell infusions have proven for the first time in the US to be feasible and safe in three humans with refractory heme malignancies and sarcoma, though it remains to be seen if it was safe for the cancers too. | Stadtmauer, ASH 2019